Compare · BSX vs NMTC
BSX vs NMTC
Side-by-side comparison of Boston Scientific Corporation (BSX) and NeuroOne Medical Technologies Corporation (NMTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NMTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 3673.8x NMTC ($19.7M).
- Over the past year, BSX is down 55.3% and NMTC is down 55.0% - NMTC leads by 0.3 points.
- BSX has been more active in the news (11 items in the past 4 weeks vs 2 for NMTC).
- BSX has more recent analyst coverage (25 ratings vs 4 for NMTC).
- Company
- Boston Scientific Corporation
- NeuroOne Medical Technologies Corporation
- Price
- $47.51-4.72%
- $2.12+0.00%
- Market cap
- $72.26B
- $19.7M
- 1M return
- +3.19%
- +23.98%
- 1Y return
- -55.27%
- -54.99%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 4
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
Latest NMTC
- SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by NeuroOne Medical Technologies Corporation
- New insider Pratt Brian claimed ownership of 1,085,934 shares (SEC Form 3)
- Market Development Director Christianson Mark sold $31,773 worth of shares (10,000 units at $3.18), decreasing direct ownership by 33% to 20,692 units (SEC Form 4)
- SEC Form 424B5 filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Amendment: SEC Form 10-Q/A filed by NeuroOne Medical Technologies Corporation
- SEC Form SD filed by NeuroOne Medical Technologies Corporation
- SEC Form SD filed by NeuroOne Medical Technologies Corporation